# Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

Source: https://onco.cc/trials/nct02485652/  
OnCo record `nct02485652` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Olmutinib in Non-small-cell lung cancer, run by Hanmi Pharmaceutical Company Limited, recorded as terminated on the registry.

## Summary

Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung is a phase 2 interventional study registered as NCT02485652 by Hanmi Pharmaceutical Company Limited, with 162 participants recorded, started 2015-08-31 and due to reach its primary completion in 2020-12-08. Interventions recorded: HM61713. Conditions recorded: Non Small Cell Lung Cancer.

Linked to the drug Olmutinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02485652
- Phase: 2
- Setting: A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
- Sponsor: Hanmi Pharmaceutical Company Limited
- Enrolled: 162

## Sources

- ClinicalTrials.gov NCT02485652: https://clinicaltrials.gov/study/NCT02485652

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Olmutinib](https://onco.cc/drugs/olmutinib/)
- companies: [Hanmi Pharmaceutical](https://onco.cc/companies/hanmi-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct02485652.json